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Abstract
Background: Vascular access-related infections and septicemia are the main causes of infections among hemodialysis
patients, the majority of them caused by Staphylococcus species. Acetylsalicylic acid (ASA) has recently been reported
with a probable antistaphylococcal activity. This study aimed to evaluate the effect of ASA on the risk of dialysis-related
infection and septicemia among incident chronic hemodialysis patients.
Methods: In a nested case–control study, we identified 449 cases of vascular access-related infections and septicemia,
and 4156 controls between 2001 and 2007 from our incident chronic hemodialysis patients’ cohort. Cases were
defined as patients hospitalized with a main diagnosis of vascular access-related infection or septicemia on the
discharge sheet (ICD-9 codes). Up to ten controls per case were selected by incidence density sampling and matched
to cases on age, sex and follow-up time. ASA exposure was measured at the admission and categorized as: no use, low
dose (80–324 mg/d), high dose (≥325 mg/d). Odds ratios (OR) for infections were estimated using multivariable
conditional logistic regression analysis, adjusting for potential confounders.
Results: Compared to no use, neither dose of ASA was associated with a decreased risk of infection: low dose (OR 1.03,
95 % CI 0.82-1.28) and high dose (OR 1.30, 95 % CI 0.96-1.75). However, diabetes (OR = 1.32, 95 % CI = 1.07–1.62) and
anticoagulant use (OR = 1.62, 95 % CI = 1.30–2.02) were associated with a higher risk.
Conclusion: Among hemodialysis patients, ASA use was not associated with a reduced risk of hospitalizations for
dialysis-related infections or septicemia. However, ASA may remain beneficial for its cardiovascular indications.
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Background
Infections represent a great challenge to the medical
field everywhere; especially among patients with comor-
bidities. Morbidity and mortality of infection are greater
in the dialysis population compared to the general popu-
lation [1–4]. In this population, infections explain more
than 20 % of hospitalizations and are the second leading
cause of death [5, 4, 6]. Infection-related hospitalizations
(IRH) in the hemodialysis population are often associ-
ated with hemodialysis catheters, and these have been
acknowledged as a major risk factor for bacteremia [7, 8].
It was estimated that more than 7000 serious complica-
tions of catheter-related bacteremia such as sepsis or
metastatic infections occur annually in the United States,
representing not only a burden on nephrology units, but
on the cost of healthcare as well [9]. Although classic in-
fection prevention strategies such as aseptic protocol,
water quality assessment and avoidance of catheters
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remain essential, we are in dire of new modifiable risk
factors.
While mostly used for its antiplatelet activity, acetyl-
salicylic acid (ASA) has been reported in vitro and in
vivo as having an antistaphylococcal activity through its
major metabolite, salicylic acid, mitigating α-hemolysin
secretion and fibronectin binding [10]. In a relatively
small study, ASA has been associated with a decreased
risk of Staphylococcus aureus bacteremia in hemodialysis
patients [11]. However, preventing one germ may not
impact on the overall infection risk as other germs
compete at the infection site. A survey of access-related
bacteremias in hemodialysis conducted in the province
of Quebec showed that S. aureus accounts for 54 % of
isolated germs, followed by Enterobateria and coagulase
negative Staphylococci with 11 % each [12]. Moreover,
because the dialysis population is at high risk of bleed-
ing events and that ASA may be potentially harmful, the
potential benefit of ASA on infections should be clearly
established before this new indication justifies its use
[13, 14]. Therefore, this study sought to evaluate the as-
sociation between ASA and the risk of dialysis-related
infections or septicemia in an incident chronic hemodialysis
cohort.
Methods
Study population and data sources
We conducted a population-based retrospective nested
case–control study to assess the association between
ASA and dialysis-related infections or septicemia leading
to a hospitalization among incident chronic hemodialysis
patients. The nested case–control design is increasingly
used in epidemiologic studies. A case–control method-
ology is applied within a predefined cohort. The main
advantage is measurement of the drug exposure at the
event instead of the beginning of the follow-up, an im-
portant issue in pharmacoepidemiology since patients
may start and stop medication during follow-up. A limit
of this method is a slightly decreased statistical power
[15, 16]. Study data were obtained from the Canadian
Organ Replacement Register (CORR) and the Régie de
l’assurance maladie du Québec (RAMQ). The CORR
gathers information on organ transplantation and dona-
tion in addition to information concerning end-stage
renal disease (ESRD) with respect to patients and facil-
ities in Canada. The RAMQ is the single-payer of a pro-
vincial health insurance plan provided to all residents of
the Province of Québec, Canada, that covers medical
and hospital services. This administrative database pro-
vides information on all medical visits, diagnostic codes
(using International Classification of Diseases – ICD),
medical procedures during in- and outpatient encounters,
and hospital discharge summaries (Med-Echo). The Med-
Echo database provides details on the date of admission
and discharge, primary and secondary diagnoses, and the
procedures performed during the hospital stay. Moreover,
all individuals aged 65 years and older, individuals on wel-
fare and workers not insured by a private insurance com-
pany are covered by the provincial drug plan. This allowed
us to obtain all drug dispensed during the study period,
including date of prescription, days of supply and daily
dose of more than 87 % of ESRD patients.
Study cohort
Derivation of the incident hemodialysis cohort was
described previously [17]. Patients initiating chronic
hemodialysis between January 1st, 2001 and December
31st, 2007 and identified in both CORR and RAMQ data
sources were included in the cohort. We excluded pa-
tients who had a prior kidney transplant or had less than
90 days of dialysis following the initiation of dialysis.
This last exclusion criterion was used to ensure that our
cohort included only chronic hemodialysis patients, and
to make it comparable to other ESRD cohorts. To ascer-
tain inclusion of incident patients only, we used a 2-year
look back period before the first dialysis code after
January 2001. Patients were followed from initiation of
hemodialysis to death, kidney transplantation, end of
the study period, or first hospitalization for dialysis-
related infection or septicemia.
Case definition: dialysis-related infections and septicemia
We identified all hospital admissions during the study
period with an ICD-9 code (or ICD-10 after 2006) indi-
cating a dialysis-related infection or septicemia as main
diagnosis on the hospital’s discharge sheet (Table 1). If a
patient was hospitalized more than once for this reason,
we only considered the first hospitalization that occurred
between the initiation of treatment and the end of the
study period. The analysis was restricted to cases who
were enrolled in the RAMQ drug plan for at least 3
months prior to the index date in order to exclude pa-
tients who might benefit from a private insurance (in
which case ASA use would not be captured). The index
date was considered to be the date of the first admission
for cases.
Control selection
For each case, up to ten controls were randomly selected
using the incidence density sampling method and
matched on age (±5 years), sex, and follow-up time
(±90 days). As for cases, controls had to be enrolled in
the RAMQ drug plan for at least three months prior to
the index date. Patients included in the cohort could
serve as a case, once or several times as a control prior
to being assessed as a case; or both, at different time
points (explaining higher counts in controls than in the
overall number of patients).
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ASA exposure
Exposure to ASA was assessed at the index date. For
each ASA prescription dispensed during follow-up, we
defined a prescription period, which was the time from
the drug dispensation date plus the number of days sup-
plied plus a tolerance period of 30 days [18]. For each
case and control, we determined if the index date was
covered by these prescription periods, and then assigned
them to one of three categories: 1) not exposed; 2) a
daily dose of 80 to 324 mg of ASA; or 3) a daily dose of
at least 325 mg of ASA. These dose categories were se-
lected according to prior studies showing that the anti-
staphyloccocal effect of ASA is independent of the
antiplatelet effect and was mostly reported with a daily
dose of 325 mg [11, 10, 19].
Covariates
Age, sex, race, body mass index (BMI), smoking status,
and laboratory data were measured at dialysis initiation.
Estimated glomerular filtration rate (eGFR) was calcu-
lated using the four-variable MDRD equation [20]. Vari-
ous co-morbidities were assessed using ICD-9 codes
from the RAMQ billing database and CORR data within
two years prior to dialysis initiation: cardiovascular dis-
ease, cerebrovascular disease, chronic pulmonary dis-
ease, chronic liver disease, congestive heart failure,
diabetes, hyperlipidemia, hypertension, malignancy, and
peripheral vascular disease. Anticoagulant and antiplate-
let (other than aspirin) use was assessed at dialysis initi-
ation using the same methodology as for ASA exposure.
Statistical analysis
Age, BMI and laboratory values are expressed as mean
and standard deviation (SD), wherever appropriate. Base-
line characteristics between cases and controls were com-
pared using the Student’s t-test or the Chi-squared test.
Odds ratios (OR) and 95 % confidence interval (CI) were
estimated using multivariable conditional logistic regres-
sion analysis. For missing laboratory values, a multiple im-
putation method was used [21]. In addition, an interaction
analysis was performed between exposure to ASA and
vascular disease, diabetes and anticoagulant use.
Ethical considerations
This study was approved by the Government of Quebec
ethics’ committee (Commission d’accès à l’information –
CAI) and the Maisonneuve-Rosemont Hospital ethics’
committee. The ethics committee waived the require-
ment for informed consent for this study.
Results and discussion
We identified a cohort of 4933 patients initiating chronic
hemodialysis during the study period. 446 patients had at
least one hospitalization for a dialysis-related infection or
a septicemia (cases). Cases were matched to 4126 controls
during the study period. The overall median follow-up
time was 1.81 years (interquartile range: 0.88-3.10 years).
Cases had a median time to first hospitalization of
0.92 years (interquartile range: 0.36-1.95 years). Character-
istics for cases and controls are shown in Table 2. Cases
were younger (66.5 versus 68.1 years), and had a higher
prevalence of diabetes (57.9 % versus 53.1 %) than con-
trols. In addition, a higher proportion of cases was using
anticoagulant drugs than controls (28.9 % versus 21.2 %).
There was no difference with respect to exposure to ASA
between cases and controls.
Adjusted OR for dialysis-related infections and septi-
cemia are presented in Table 3. Regardless of the dose,
ASA use was not associated with a reduced risk of
dialysis-related infections or septicemia (OR = 1.02
[95 % CI: 0.82-1.26] for <325 mg and OR = 1.17 [95 %
CI: 0.87-1.58] for ≥325 mg) compared to unexposed.
Among covariates, diabetes (OR = 1.30 [95 % 1.05-1.62])
and concurrent anticoagulant use (OR = 1.61 [95 % CI:
1.29-2.01]) were associated with a higher risk of dialysis-
related infection and septicemia.
The interaction between exposure to ASA and vascu-
lar disease (p = 0.72 and p = 0.20), diabetes (p = 0.59 and
p = 0.22) or concurrent anticoagulant (p = 0.97 and
Table 1 Definition of dialysis-related infection or septicemia (ICD-9 and ICD-10 codes and their description)
ICD-9 codes ICD-10 codes Description
038 A40 -A41 Streptococcal septicemia, Staphylococcal septicemia, Pneumococcal septicemia
[Streptococcus pneumoniae septicemia], Septicemia due to anaerobes, Septicemia
due to other gram-negative organisms, Other specified septicemias, Unspecified septicemia
112.5 B37.7 Candidal sepsis
790.7 Bacteremia
785.52 R57.2 Severe sepsis with septic shock
996.62 T82.7 Infection and inflammatory reaction due to other cardiac and vascular devices,
implants and grafts, initial encounter
996.69 T85.7 Infection and inflammatory reaction due to other internal prosthetic devices,
implants and grafts, initial encounter
ICD International Classification of Diseases
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p = 0.41) use was not statistically significant for low
dose and high dose of ASA respectively.
The results of this large multicenter population-based
study showed no association between ASA use and
dialysis-related infection and septicemia in the chronic
hemodialysis population.
Salicylic acid, a major metabolite of ASA, has been
shown to reduce the expression of two virulence factors
of S. aureus: α-hemolysin and fibronectin gene pro-
moters [10]. Few observational studies evaluated the po-
tential antimicrobial effect of ASA use as an adjunctive
treatment in infective endocarditis, and found opposing
results [22–24]. However, a randomized-control trial in
115 patients showed no beneficial effect and a potential
increase in bleeding risk [25, 19]. To our knowledge,
only one prior clinical study evaluated the potential
benefit of ASA as an antimicrobial in dialysis patients.
Among 872 hemodialysis patients with tunneled cathe-
ters, ASA was associated with a 54 % decreased risk of
developing a S. aureus bacteremia [11]. These different
results from our study may be explained by the fact that
we considered all bacteria (and not only S. aureus). In-
deed, when all pathogens were considered, bacteremia
Table 2 Characteristics for cases and controls
Patients’ characteristics Cases Controls P-value
N = 446 N = 4126
Age (years) 66.5 ± 12.8 68.1 ± 10.8 0.01
Female sex (%) 42.4 40.8 0.52
Race (%)
Black 6.0 4.1 0.16
Caucasian 84.5 86.1
Other 9.4 9.8
BMI (kg/m2) 27.8 ± 6.3 27.4 ± 6.3 0.29
Smoking (%) 15.5 14.1 0.41
Co-morbidities (%)
Cardiovascular disease 57.9 58.2 0.87
Cerebrovascular disease 17.7 16.3 0.46
Chronic pulmonary disease 32.5 30.0 0.27
Chronic liver disease 2.2 3.1 0.33
Congestive heart failure 37.4 37.8 0.89
Diabetes 57.9 53.1 0.05
Hyperlipidemia 58.3 58.7 0.87
Hypertension 94.8 94.1 0.52
Malignancy 17.7 16.7 0.60
Peripheral vascular disease 37.4 36.7 0.75
ASA daily dose
Unexposed 50.7 49.3 0.79
80-324 mg 35.7 37.3
≥ 325 mg 13.7 13.4
Other medication use (%)
Anticoagulant 28.9 21.2 >0.001
Antiplatelet 11.0 11.8 0.63
Laboratory data
Albumin (g/L) 33.2 ± 6.6 33.9 ± 6.5 0.09
eGFR (ml/min•1.73 m2) 9.0 ± 3.7 9.1 ± 4.0 0.65
Hemoglobin (g/L) 10.2 ± 1.8 10.5 ± 1.8 0.01
Units conversion: Albumin, divide by 10 to convert g/L to g/dL; Hemoglobin,
divide by 10 to convert g/L to g/dL
BMI body mass index; eGFR estimated glomerular filtration rate
Table 3 Adjusted odds ratios for dialysis-related infection or
septicemia
Variable Crude OR Adjusted ORa
OR 95 % CI OR 95 % CI
Age (by 1 year) 0.87 0.62 , 1.23 0.86 0.71 , 1.04
Race
Black 1.35 0.88 , 2.08 1.37 0.9 , 2.08
Caucasian 1.00 Reference 1.00 Reference
Other 0.94 0.67 , 1.32 0.95 0.7 , 1.3
BMI (by 5 kg/m2) 1.05 0.97 , 1.14 1.01 0.93 , 1.11
Smoking 1.12 0.85 , 1.47 1.1 0.84 , 1.44
Co-morbidities
Cardiovascular disease 1.11 0.90 , 1.36 1.01 0.79 , 1.28
Cerebrovascular disease 1.16 0.89 , 1.50 1.1 0.84 , 1.43
Chronic pulmonary disease 1.18 0.96 , 1.46 1.15 0.92 , 1.43
Chronic liver disease 0.77 0.40 , 1.47 0.71 0.38 , 1.32
Congestive heart failure 1.05 0.86 , 1.29 0.91 0.73 , 1.14
Diabetes 1.31 1.07 , 1.61 1.3 1.05 , 1.62
Hyperlipidemia 1.07 0.87 , 1.31 0.98 0.78 , 1.22
Hypertension 1.22 0.78 , 1.90 1.17 0.77 , 1.77
Malignancy 1.13 0.87 , 1.46 1.17 0.91 , 1.51
Peripheral vascular disease 1.09 0.88 , 1.34 1.01 0.81 , 1.24
ASA daily dose
Unexposed 1.00 Reference 1.00 Reference
80-324 mg 0.99 0.80 , 1.24 1.02 0.82 , 1.26
≥ 325 mg 1.06 0.78 , 1.44 1.17 0.87 , 1.58
Other medication use
Anticoagulant 1.57 1.26 , 1.96 1.61 1.29 , 2.01
Antiplatelet 0.96 0.70 , 1.32 0.97 0.7 , 1.33
Laboratory data
Albumin (by 10 g/L) 0.85 0.71 , 1.02 0.93 0.79 , 1.10
eGFR (ml/min•1.73 m2) 1.00 0.97 , 1.03 1.00 0.97 , 1.03
Hemoglobin (by 10 g/L) 0.93 0.88 , 0.99 0.94 0.89 , 1.00
Unit conversion: Albumin, multiply by 10 to convert g/dL to g/L; Hemoglobin,
multiply by 10 to convert g/dL to g/L
BMI body mass index; eGFR estimated glomerular filtration rate
aAdjusted for demographics, body mass index, smoking, comorbidities,
anticoagulant use, antiplatelet use, and laboratory values
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was not significantly reduced by ASA in the Sedlacek et al.
study [11]. While reducing S. aureus bacteremia is import-
ant as it is associated with high morbidity and mortality, it
remains important to evaluate infections from all other
pathogens as they may take the place left by S. aureus re-
duction. Such a phenomenon was shown in some studies
evaluating S. aureus nasal carriage eradication, where inci-
dence of infections from other germs than S. aureus in-
creased [26]. Unfortunately, microorganisms information
was not available to us while conducting this study.
The dose of ASA may play an important role as earlier
studies have reported an antistaphylococcal effect of
ASA when using a daily dose of 325 mg, but not with
the 80 mg daily dose [11, 10, 19]. This is probably ex-
plained by the fact that the antistaphylococcal effect is
mediated by salicylic acid, and is therefore independent
of the antiplatelet effect [10]. However, in the present
study, both dose categories were not associated with de-
creased risk of dialysis-related infections and septicemia.
Consistent with literature, we found that diabetes was
associated with an increased risk of infection [11, 8]. We
also found that anticoagulant use was associated with a
61 % increase risk of dialysis-related infection and septi-
cemia. While anticoagulant use is not a known risk fac-
tor for infection, it may be a proxy for catheter use in
our cohort (anticoagulant may be used for dysfunctional
catheters), which is a strong risk factor for infection [8].
Strengths of this study are its large size leading to high
statistical power, the large number of included covariates,
and the fact that it is conducted in a universal health care
system setting, limiting potential selection bias. However,
this study has also some limitations. First, because infec-
tions are identified through hospital discharge sheets, our
study is limited to cases of serious dialysis-related infec-
tions and septicemia requiring hospitalizations.
The use of diagnostic codes does not prevent from
underestimating the number of cases. Only the code for
the main diagnosis was considered for this study. Infec-
tions recorded as secondary diagnoses could have been
caused by many reasons, and their inclusion in the study
would have introduced an important confounding bias
limiting the interpretation of the results. While it is pos-
sible that ASA may only reduce less severe infections,
we believe that we identified the most clinically import-
ant events. Because ASA can be obtained over-the-
counter, our study is subject to misclassification bias.
However, due to financial incentives and the facts that
hemodialysis patients have already numerous medica-
tions, it is estimated that the proportion of patients
using ASA chronically over-the-counter is low. Despite
adjusting for various variables, our study remains prone
to residual confounding. Indeed, catheter-related infec-
tions are a major cause of infection in this population,
but data on catheter use was missing in our database.
For reference, 54.4 % of prevalent hemodialysis patients
were using a tunneled catheter in 2013 in Quebec [12].
Because the type of vascular access is not an indication
or a contraindication to ASA use, we believe that its use
should not differ by vascular access type.
Conclusion
We have shown that the use of ASA is not associated
with a reduced overall risk of hospitalization for dialysis-
related infections or septicemia in the dialysis popula-
tion. Further studies are needed to determine if ASA
modifies the microorganisms’ distribution of these infec-
tions, and possibly improving outcomes. Before these
studies are conducted, the potential risk of bleeding as-
sociated with ASA may limit the use of ASA for preven-
tion of infection. However, ASA may remain beneficial
for its cardiovascular indications.
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